keyword
MENU ▼
Read by QxMD icon Read
search

Elderly and nhl

keyword
https://www.readbyqxmd.com/read/29748444/rituximab-plus-bendamustine-as-front-line-treatment-in-frail-elderly-70-years-patients-with-diffuse-large-b-cell-non-hodgkin-s-lymphoma-a-phase-ii-multicenter-study-of-the-fondazione-italiana-linfomi
#1
Sergio Storti, Michele Spina, Emanuela Anna Pesce, Flavia Salvi, Michele Merli, Alessia Ruffini, Giuseppina Cabras, Annalisa Chiappella, Emanuele Angelucci, Alberto Fabbri, Anna Marina Liberati, Monica Tani, Gerardo Musuraca, Annalia Molinari, Maria Pia Petrilli, Carmela Palladino, Rosanna Ciancia, Andrea Ferrario, Cristiana Gasbarrino, Federico Monaco, Vincenzo Fraticelli, Annalisa De Vellis, Francesco Merli, Stefano Luminari
We conducted a phase II study to assess activity and safety profile of bendamustine and rituximab in elderly patients with untreated Diffuse Large B Cell Lymphoma who were prospectively defined as frail using a simplified version of a Comprehensive Geriatric Assessment. Patients had to be > 70 years of age, with histologically confirmed Diffuse Large B Cell Lymphoma. Frail patients were those younger than 80 years with a frail profile at Comprehensive Geriatric Assessment or older than 80 years with an unfit profile...
May 10, 2018: Haematologica
https://www.readbyqxmd.com/read/29747287/-a-comparative-study-of-comprehensive-geriatric-assessment-in-elder-patients-with-non-hodgkin-s-lymphoma
#2
H Liu, M Gao, D Mei, H X Han, J T Li, J F Bai, C L Zhang, R Feng, J P Wei, Y Tian, T Wang
Objective: To measure the comprehensive geriatric assessment (CGA) in elder non-Hodgkin's Lymphoma (NHL) patients in a cross-sectional study; to compare the differences between Eastern Cooperative Oncology Group (ECOG)-performance status (PS) and CGA. Methods: CGA stratification included the following 3 instrument assessments: activity of daily living (ADL);instrumental activity of daily living (IADL);comorbidity score according to the modified cumulative illness rating score for geriatrics (MCIRS-G). According to CGA and age, NHL patients, aged ≥60 years, were classified as"fit","unfit"and"frail"groups...
May 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/29673807/frequency-and-impact-of-grade-three-or-four-toxicities-of-novel-agents-on-outcomes-of-older-patients-with-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma-alliance-a151611
#3
Michael Tallarico, Jared C Foster, Drew Seisler, Jacqueline M Lafky, Arti Hurria, Aminah Jatoi, Harvey J Cohen, Hyman B Muss, Nancy Bartlett, Bruce D Cheson, Sin-Ho Jung, John P Leonard, John C Byrd, Chadi Nabhan
OBJECTIVE: Older patients with cancer suffer from chemotherapy-related toxicities more frequently than younger patients. As novel agents are being used more commonly in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), toxicities of these agents in older patients have not been well studied. Further, impact of these toxicities on outcomes in the elderly is unknown. This study aimed to answer both questions. PATIENTS AND METHODS: We reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004-2014...
April 16, 2018: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/29669178/the-utility-of-multiparametric-flow-cytometry-in-the-detection-of-primary-effusion-lymphoma-pel
#4
Jacobo Galán, Isaac Martin, Itziar Carmona, José María Rodriguez-Barbero, Esperanza Cuadrado, Luis García-Alonso, José Antonio García-Vela
Primary effusion lymphoma (PEL) is a rare B cell lymphoproliferative disorder that arises predominantly in body cavities causing malignant effusions.The incidence of PEL is very low, accounting for approximately 4% of all HIV-associated non-Hodgkin lymphomas. PEL has also been described in elderly patients and after solid-organ transplantation. It is associated in all cases with human herpesvirus 8 (HHV8). We describe a case of PEL in a 88-year-old HIV-negative woman who presented with progressive dyspnea and moderate right-sided pleural effusion without significate lymphadenopathies or other effusions...
April 18, 2018: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/29551465/the-possible-role-of-maintenance-treatment-for-primary-central-nervous-system-lymphoma
#5
REVIEW
Osnat Bairey, Tali Siegal
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive brain tumor. The prognosis is poor, with high rates of relapse and disease progression after treatment. In addition, PCNSL affects a largely older population, so that a significant proportion of patients are ineligible for intensive therapies and high-dose chemotherapy. The elderly patients are also susceptible to the accelerated and detrimental cognitive side effects of whole-brain irradiation which is an alternative consolidation to high-dose chemotherapy...
March 11, 2018: Blood Reviews
https://www.readbyqxmd.com/read/29385883/successful-use-of-cytarabine-and-bendamustine-in-a-patient-with-mantle-cell-lymphoma-and-acute-renal-failure-using-intermittent-hemodialysis-a-case-report
#6
Matthew Ettleson, Kale S Bongers, Kaitlyn Vitale, Anthony J Perissinotti, Tycel Phillips, Bernard L Marini
Mantle cell lymphoma is a mature B-cell non-Hodgkin lymphoma characterized by the hallmark (11;14) chromosomal translocation, which often presents with lymphadenopathy and extra-nodal involvement. Young, fit patients are generally treated with chemotherapy approaches that incorporate high-dose cytarabine (e.g. the Nordic regimen) followed by autologous hematopoietic cell transplantation. Because of the significant activity of cytarabine in mantle cell lymphoma, increasingly, high- and intermediate-dose cytarabine are being used in the treatment of elderly mantle cell lymphoma patients...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29362299/-risk-assessment-of-hematologic-malignancy-treatment-of-the-elderly
#7
Hidenori Sasaki, Yasushi Takamatsu
Along with the aging society in Japan, the number ofelderly cancer patients is increasing, and hematological malignancy is no exception. Treatment ofhematological malignancy is mainly chemotherapy and furthermore it is necessary to keep its dose intensity. In the elderly, adverse events may be strong due to deterioration oforgan function, comorbidity, etc., and it is difficult for individual differences to decide chemotherapy regimen and dose. Geriatric assessment(GA)used in the field of geriatric medicine is reported to be useful for risk assessment of chemotherapy...
January 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29304125/a-purified-fermented-extract-of-triticum-aestivum-has-lymphomacidal-activity-mediated-via-natural-killer-cell-activation
#8
Gustavo A Barisone, Robert T O'Donnell, Yunpeng Ma, Mastewal W Abuhay, Kathleen Lundeberg, Sonia Gowda, Joseph M Tuscano
Non-Hodgkin lymphoma (NHL) affects over 400,000 people in the United States; its incidence increases with age. Treatment options are numerous and expanding, yet efficacy is often limited by toxicity, particularly in the elderly. Nearly 70% patients eventually die of the disease. Many patients explore less toxic alternative therapeutics proposed to boost anti-tumor immunity, despite a paucity of rigorous scientific data. Here we evaluate the lymphomacidal and immunomodulatory activities of a protein fraction isolated from fermented wheat germ...
2018: PloS One
https://www.readbyqxmd.com/read/29284757/autologous-stem-cell-transplantation-in-elderly-lymphoma-patients-in-their-70s-outcomes-and-analysis
#9
Lova Sun, Shuli Li, Areej El-Jawahri, Philippe Armand, Bimalangshu R Dey, David C Fisher, Eric D Jacobsen, Caron A Jacobson, Ann S LaCasce, Steven L McAfee, Thomas R Spitzer, Yi-Bin Chen, Zachariah DeFilipp
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma. However, elderly patients are often not considered ASCT candidates based on age alone. SUBJECTS, MATERIALS, AND METHODS: A retrospective analysis of patients ≥70 years of age with a diagnosis of Hodgkin or non-Hodgkin lymphoma receiving ASCT between 2000 and 2016 at two partner institutions was performed...
December 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29274153/oral-cancer-a-multicenter-study
#10
K Dhanuthai, S Rojanawatsirivej, W Thosaporn, S Kintarak, A Subarnbhesaj, M Darling, E Kryshtalskyj, C-P Chiang, H-I Shin, S-Y Choi, S-S Lee, P Aminishakib
BACKGROUND: To determine the prevalence and clinicopathologic features of the oral cancer patients. MATERIAL AND METHODS: Biopsy records of the participating institutions were reviewed for oral cancer cases diagnosed from 2005 to 2014. Demographic data and site of the lesions were collected. Sites of the lesion were subdivided into lip, tongue, floor of the mouth, gingiva, alveolar mucosa, palate, buccal/labial mucosa, maxilla and mandible. Oral cancer was subdivided into 7 categories: epithelial tumors, salivary gland tumors, hematologic tumors, bone tumors, mesenchymal tumors, odontogenic tumors, and others...
January 1, 2018: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/29232438/refractory-or-relapsed-aggressive-b-cell-lymphoma-failing-r-chop-an-analysis-of-patients-treated-on-the-ricover-60-trial
#11
B Glass, A J Dohm, L H Truemper, M Pfreundschuh, A Bleckmann, G G Wulf, A Rosenwald, M Ziepert, N Schmitz
Background: The prognosis of elderly patients with aggressive B-non-Hodgkin's lymphoma after first lymphoma-related treatment failure (TF-L) is not well described. Methods: We analysed patient characteristics including the presence of MYC rearrangements and MYC-expression immunohistochemistry (IHC) at diagnosis and modalities of salvage therapy and their impact on the prognosis of patients between 61 and 80 years who had been treated on the RICOVER-60 trial. Results: TF-L occurred in 301 of the 1222 (24...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29212420/durable-response-after-vncop-b-and-rituximab-in-an-elderly-patient-with-high-grade-b-cell-lymphoma
#12
Emanuele Cencini, Alberto Fabbri, Luana Schiattone, Francesco Gentili, Maria Antonietta Mazzei, Monica Bocchia
OBJECTIVES AND METHODS:  High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients...
December 6, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29200113/primary-central-nervous-system-lymphoma
#13
Catherine H Han, Tracy T Batchelor
PURPOSE OF REVIEW: Primary central nervous system (CNS) lymphoma is a rare and aggressive extranodal non-Hodgkin lymphoma confined to the brain, eyes, spinal cord, or leptomeninges without systemic involvement. This article provides an overview of the clinical features, diagnosis, and management of primary CNS lymphoma in patients who are immunocompetent, focusing on recent advances in treatment. RECENT FINDINGS: Primary CNS lymphoma is sensitive to radiation therapy; however, whole-brain radiation therapy inadequately controls the disease when used alone and causes delayed neurotoxicity with significant neurocognitive impairment, especially in patients who are elderly...
December 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29193018/obesity-negatively-impacts-outcome-in-elderly-female-patients-with-aggressive-b-cell-lymphomas-treated-with-r-chop-results-from-prospective-trials-of-the-german-high-grade-non-hodgkin-s-lymphoma-trial-group
#14
K Hohloch, B Altmann, M Pfreundschuh, M Loeffler, N Schmitz, F Zettl, M Ziepert, L Trümper
To study if obesity is a risk factor in elderly patients (>60 years) with aggressive B-cell lymphoma, the outcomes of 576 elderly patients treated with rituximab in the RICOVER-60 trial were analysed in a retrospective study with regard to body mass index (BMI) and gender. Of the 576 patients, 1% had low body weight (BMI < 18·5), 38% were normal weight (18·5 ≤ BMI < 25), 42% were overweight (25 ≤ BMI < 30) and 19% were obese (BMI ≥ 30). Event-free (EFS), progression-free (PFS) and overall survival (OS) according to BMI showed no significant differences for all and for male patients...
January 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29172868/treatment-for-patients-with-relapsed-refractory-mantle-cell-lymphoma-european-based-recommendations
#15
Martin Dreyling, Igor Aurer, Sergio Cortelazzo, Olivier Hermine, Georg Hess, Mats Jerkeman, Steven Le Gouill, Vincent Ribrag, Marek Trněný, Carlo Visco, Jan Walewski, Francesco Zaja, Pier Luigi Zinzani
Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed...
November 27, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29170864/risk-of-malignancy-in-a-nationwide-cohort-of-elderly-inflammatory-bowel-disease-patients
#16
Nabeel Khan, Carlos Vallarino, Trevor Lissoos, Umar Darr, Michelle Luo
BACKGROUND: Management of elderly inflammatory bowel disease (IBD) patients (≥ 65 years of age) is complicated due to many factors, including a higher risk of cancer, which may impact therapeutic decisions. OBJECTIVE: The aim of this study was to determine the risk of cancer among elderly IBD patients compared with younger IBD patients. Additionally, the absolute risk of malignancy and factors contributing to it were evaluated, and therapeutic patterns among the elderly were assessed...
November 2017: Drugs & Aging
https://www.readbyqxmd.com/read/29153347/autologous-stem-cell-transplantation-and-stem-cell-mobilization-kinetics-in-elderly-patients-with-b-cell-non-hodgkin-lymphoma
#17
Mehmet Hilmi Dogu, Seçkin Çagirgan, Serkan Ocakci, Ali Hakan Kaya, Kadir Ilkkilic, Neslihan Mandaci Sanli, Selda Kahraman, Rafet Eren, Emre Tekgunduz, Sibel Hacioglu, Leylagul Kaynar, Mehmet Ali Erkurt, Fevzi Altuntas
As known, the world population is aging and as the life span increases the number of advanced-age lymphomas also shows an upward trend. Autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment modality in chemotherapy-sensitive relapsed or refractory aggressive lymphomas. Increased morbidity and mortality related to both the transplant itself and comorbid diseases can be observed in elderly lymphoma patients. Patients who are 65 years or older and underwent autologous HSCT with B-cell non-Hodgkin lymphoma were retrospectively included in our study...
December 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29143301/potentially-inappropriate-medication-use-in-elderly-non-hodgkin-lymphoma-patients-is-associated-with-reduced-survival-and-increased-toxicities
#18
Richard J Lin, Helen Ma, Robin Guo, Andrea B Troxel, Catherine S Diefenbach
Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis for 171 elderly patients (median age 70 years) with aggressive non-Hodgkin lymphoma treated between 2009 and 2014. At least one potentially inappropriate medication was used in 47% of patients according to the Beers Criteria, 59% experienced treatment delays and/or dose reduction and 65% experienced ≥ grade 3 treatment-related toxicities. We report here for the first time that potentially inappropriate medication use was associated with reduced progression-free survival and overall survival, and increased ≥ grade 3 treatment-related toxicities in multivariate analysis...
January 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29141942/frailty-and-the-management-of-hematologic-malignancies
#19
REVIEW
Gregory A Abel, Heidi D Klepin
The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma...
February 1, 2018: Blood
https://www.readbyqxmd.com/read/29119031/pediatric-pulmonary-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-the-literature
#20
Eric X Wei, Roberto F Silva, James D Cotelingam, Rodney E Shackelford
Non-Hodgkin's lymphoma (NHL) is a common malignancy of childhood; however, a lung primary presentation is an uncommon finding, as is finding an association with the Epstein-Barr virus (EBV). We report the case of a 23-month-old female who developed EBV-associated diffuse large B-cell lymphoma (DLBCL) that was initially thought to be pneumonia. Extensive tissue necrosis, focal angioinvasion, and angiodestruction were observed. She was refractory to various therapy regimens, subsequently developed DLBCL in the central nervous system, and eventually expired...
2017: Case Reports in Pathology
keyword
keyword
81032
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"